Fig. 4
Cumulative NMA overall survival results of subgroup analyses for the pairwise comparisons a AC-TH52 weeks vs. AC-T, b TCH52 weeks vs. AC-T, and c AC-TH52 weeks vs. TCH52 weeks. Boxes on the forest plots represent the hazard ratios, with 95% CrIs shown by the horizontal lines. The size of each box is based on the precision of each effect estimate. The x axis is presented in log format. AC anthracycline (doxorubicin, epirubicin) + cyclophosphamide, CrI credible interval, H Herceptin® intravenous (IV), NA not available, T taxane (docetaxel, paclitaxel), TCH docetaxel + carboplatin + Herceptin® IV